Evidence map›Paper›PMID 21819585›Full record

ArticleRetrovirology2011

Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2.

Kevin C Olivieri, Joya Mukerji, Dana Gabuzda

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kevin C OlivieriDepartment of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA, USA.
Joya Mukerji
Dana Gabuzda
Dana-Farber Cancer Institute · USHarvard University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Training in the Molecular Biology of Neurodegeneration and Alzheimer's DiseaseT32AG000222 · NIA · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Bruce A YANKNER · 1992 to 2026
$18.5M
Postdoctoral Training Program in AIDS-related ResearchT32AI007386 · NIAID · DANA-FARBER CANCER INSTITUTE · PI CANTOR, HARVEY, ENGELMAN, ALAN N. · 1990 to 2023
$5.3M
Systems Biology of Immune Reconstitution in HIV / AIDSDP1DA028994 · NIDA · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2009 to 2014
$4.3M
HIV Nef-MEDIATED ENHANCEMENT OF T CELL ACTIVATION VIA PAK2R21AI073415 · NIAID · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2007 to 2008
$466k
Regulation of T cell activation by HIV NefR21AI077464 · NIAID · DANA-FARBER CANCER INST · PI GABUZDA, DANA H. · 2008 to 2009
$299k
NIAID NIH HHS P30 AI060354NIAID NIH HHS R21 AI073415NIAID NIH HHS R21 AI077464NIAID NIH HHS R21 AI73415NIAID NIH HHS R21 AI77464NIAID NIH HHS T32 AI007386NIA NIH HHS T32 AG00222NIDA NIH HHS DP1 DA028994
6 · The paper itself

Abstract

backgroundThe HIV-1 accessory protein Nef is an important determinant of lentiviral pathogenicity that contributes to disease progression by enhancing viral replication and other poorly understood mechanisms. Nef mediates diverse functions including downmodulation of cell surface CD4 and MHC Class I, enhancement of viral infectivity, and enhancement of T cell activation. Nef interacts with a multiprotein signaling complex that includes Src family kinases, Vav1, CDC42, and activated PAK2 (p21-activated kinase 2). Although previous studies have attempted to identify a biological role for the Nef-PAK2 signaling complex, the importance of this complex and its constituent proteins in Nef function remains unclear.

resultsHere, we show that Nef mutants defective for PAK2-association, but functional for CD4 and MHC Class I downmodulation and infectivity enhancement, are also defective for the ability to enhance viral replication in primary T cells that are infected and subsequently activated by sub-maximal stimuli (1 μg/ml PHA-P). In contrast, these Nef mutants had little or no effect on HIV-1 replication in T cells activated by stronger stimuli (2 μg/ml PHA-P or anti-CD3/CD28-coated beads). Viruses bearing wild-type Nefs, but not Nef mutants defective for PAK2 association, enhanced NFAT and IL2 receptor promoter activity in Jurkat cells. Moreover, expression of wild-type Nefs, but not mutant Nefs defective for PAK2 association, was sufficient to enhance responsiveness of primary CD4 and CD8 T cells to activating stimuli in Nef-expressing and bystander cells. siRNA knockdown of PAK2 in Jurkat cells reduced NFAT activation induced by anti-CD3/CD28 stimulation both in the presence and absence of Nef, and expression of a PAK2 dominant mutant inhibited Nef-mediated enhancement of CD25 expression.

conclusionNef-mediated enhancement of cellular activation and viral replication in primary T cells is dependent on PAK2 and on the strength of the activating stimuli, and correlates with the ability of Nef to associate with PAK2. PAK2 is likely to play a role in Nef-mediated enhancement of viral replication and immune activation in vivo.

Indexed as

Virus ReplicationCD4-Positive T-LymphocytesCell LineCells, CulturedHIV-1HIV InfectionsHumansLymphocyte Activationnef Gene Products, Human Immunodeficiency Virusp21-Activated KinasesProtein Bindingnef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1p21-Activated KinasesPAK2 protein, human

Identifiers

PMID21819585
PMCPMC3169461
OpenAlexW2138528391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.